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Fig. 1: Flow-chart of the selection process.
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ABSTRACT
Objectives: During the drug development process, phase I trials are the first occasion to study the
pharmacokinetics (PK) of a drug. They are performed in healthy volunteers, or patients in oncology,
and are designed to determine a safe and acceptable dose for the later phases of clinical trials. We
performed a bibliographic survey to investigate the way PK is described and reported in phase I
clinical trials.
Methods: We performed a MEDLINE search to retrieve the list of papers published between 2005
and 2006 and reporting phase I clinical trials with a PK study. We used a spreadsheet to record general
information concerning the study, and specific information regarding the PK, such as the sampling
times, number of subjects, and method of analysis.
Results: The search yielded 349 papers, of which 37 were excluded for various reasons. Nearly all
the papers in our review concerned cancer studies, although this was not a requirement in the search.
Consistent with the selection process, 84% papers explicitly stated PK as an objective of the study.
The methods section usually included a description of the PK (88%), but 10% of the papers pro-
vided no information concerning the methods used for the PK, and in 2% the description was only
partial. The analysis method was usually basic, with non-compartmental or purely descriptive meth-
ods. Observed concentrations and area under the curves were the PK variables most often reported.
The results of the PK study were frequently reported in a separate paragraph of the results section,
and only 22% of the studies related the PK findings to other results from the study, such as toxicity or
efficacy. In addition, important information such as the number of subjects included in the PK study
or the PK sampling scheme was sometimes not reported explicitly.
Conclusion: Concerns about the decreasing cost-effectiveness in the drug development process
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prompted the regulatory authorities to recently recommend a better integration of all available in-
formation, including in particular PK, in this process. In our review we found that this information
was often either missing or incomplete, which hinders that objective. We suggest several improve-
ments to the design and the reporting of methods and results for these studies, to ensure all relevant
information has been included. PK findings should also be integrated in the broader perspective of
drug development, through the study of their relationship with toxicity and/or efficacy, even in early
phase I stages.
Keywords
pharmacokinetics; phase I trials; reporting; survey
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1 Introduction
In humans, clinical drug development is initiated with what is termed phase I trials. Phase I
trials follow in vitro analyses and extensive animal studies designed to select the starting dose for use
in humans, i.e., the maximum recommended starting dose (MRSD) [1]. Phase I represents the first
translation from basic laboratory work to the clinical setting. Usually, phase I trials are performed in
healthy subjects, except when the drug is intended for the treatment of malignancies. Such studies
are indeed characterized by the high potential toxicity of assessed drugs at any dose required to be
effective and are therefore performed in patients, often patients who have failed several previous lines
of treatments. Phase I trials are aimed at obtaining reliable information on a drug’s safety, tolerability,
pharmacokinetics (PK), and mechanism of action. More specifically, in a healthy volunteer study, the
objective is to determine the maximum safe dose under a certain PK or pharmacodynamic (PD) safety
limit; for a cancer study, the objective is to determine the maximum tolerated dose (MTD), defined
as the highest dose with a relatively low risk of dose-limiting toxicity (DLT), or to recommend a dose
level for phase II trials [2].
During phase I, sufficient information about the drug’s PK and pharmacological effects should
be obtained to permit the design of well-controlled, scientifically valid, phase II studies [3]. Phase I
studies can also be performed in later stages to investigate specific questions, such as the effect of
food, modifications encountered in special populations, or drug-drug interactions [4]. Phase I trials
therefore often include a PK study. PK studies are intended to define the time-course of drug in the
body, and are required in the registration files handed in to the regulatory authority. Furthermore, the
determination of dose-exposure-effect relationships is now recognised to be a crucial part of the drug
development process [5] and is facilitated by the expanding development of biomarkers and analytical
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techniques. Modelling and simulation tools are already extensively and successfully used in many
industrial fields outside the pharmaceutical industry, which has shown that PK/PD guided approaches
can streamline the development process [6]. The Food and Drug Administration in the US devised a
strategy, reported in March 2006 in "The Critical Path Opportunities Report", highlighting specific
areas to improve and speeden the development of new, effective and safe medicines [7]. A significant
part of that report shows how modelling and simulation techniques can be used to incorporate all
the information available from different stages of the clinical development to achieve this goal, using
successful attempts at integrated PK/PD development as examples [8].
Over the last decades, many methodological developments have been proposed to analyse data
from PK studies. A large part of these relate to the so-called population approaches, where the average
parameters and their associated variabilities are estimated through nonlinear mixed-effect models [9],
and which are invaluable when the design of the studies is sparse or variable between subjects [10].
Non-compartmental approaches and individual nonlinear regression have also been extended. Many
software have been developed to perform these different types of analyses. However, the extent to
which these methods are actually applied in clinical trials has not been evaluated.
Our aim in this paper was to evaluate, through a bibliographic survey the way PK studies of phase
I clinical trials, how these trials are reported and analysed. More specifically, we were particularly
interested in the following points: (i) the description of the PK study; (ii) the methods used to anal-
yse the data; (iii) the completeness of the results reported, (iv) the concordance between presented
methodology and reported results, and (v) whether the results are used to bring additional information
to the study. It should be noted that the aim of this paper is not to judge the quality of publications,
since there is no validated tool for that, but to see if the PK part of a published clinical trials is well
reported and can be understood by all readers.
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2 Materials and methods
2.1 Article selection
PubMed was used to retrieve the references of all the papers corresponding to the following crite-
ria: "phase I" or "phase 1" in title, pharmacokinetic* anywhere (title, abstract, keywords). The search
was limited to ’English language’ and to papers published in 2005 and 2006. The full text was then
retrieved.
2.2 Data abstraction form and analysis
Our objective was to determine how much information concerning the PK study was reported in
the papers describing the phase I study. We built a data abstraction form, which corresponds to a
checklist of items [11]. The form was then structured as a spreadsheet with each column representing
one item, and the readers filled one line for each paper read. The form was used to extract a large
number of informations from the articles and allowed statistical analysis of the results. In addition
to items describing the pharmacokinetic study of the trials, we also extracted general information
concerning the paper and the trial itself. We now describe in detail the items included in the data
abstraction form.
We first included in the spreadsheet a number of items describing the authors of the study: the
name and address of the first author, whether a statistician, a pharmacokineticist or a pharmacologist
was present amongst the co-authors (based on the affiliations). We also recorded industrial partner-
ship, by checking whether scientists from the pharmaceutical industry were co-authors, and whether
the study was sponsored by the pharmaceutical industry, based on the declarations of conflict of in-
terest and of grants received.
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The next series of items described the phase I study: the title of the paper, the journal, the year
of publication, the main drug tested and whether associated drugs have been tested, the primary and
secondary objectives of the study, the patient population (adults or children) and the disease for which
they were treated (if any). Since a large portion of phase I clinical trials deal with anticancer drugs,
we also recorded whether the tumor response was evaluated when appropriate.
Given that phase I clinical trials are designed to investigate several doses of the drug and to test
the tolerability of the drug, the next series of items described the design of the study: the number of
subjects included, the planned number of drug levels, the dose-escalation scheme, the total number of
dose-limiting toxicities that occurred during the study, whether MTD was reached or not, and whether
patient selection was performed before the analysis. If several drugs were included, double-escalation
was checked when both drugs under study were escalated, either together or sequentially.
Finally, a number of items specific to the PK analysis were then included in the spreadsheet: the
number of subjects included in the PK study, whether the PK sampling scheme was described, whether
the PK was sampled on one or more occasions, the dose levels for which PK was sampled, the PK
variables reported, and whether the relationships PK-toxicity and/or PK-efficacy were investigated.
If several drugs were included, we also recorded whether a PK interaction study was performed. In
addition, we recorded the analysis method used to analyse the PK, the software, and whether a model
was built to describe the PK.
The first 40 papers were read by both authors who then met to compare the results entered in the
data abstraction form and to assess the reproducibility between the two readers. All discordant results
were checked and corrected. The next papers were divided equally and read by only one reader.
Once the survey was completed, we used descriptive statistics (median and range) for continuous
Reporting PK in phase I clinical trials 9
variables and frequencies and percentages for categorical variables. Chi-square tests were used to
perform stratified analyses with respect to the primary objective of the study. Data management and
statistical analyses were performed using R (version 2.4.0) [12].
3 Results
3.1 General results
The flowchart resuming the selection process is given in figure 1. The keyword selection retrieved
354 papers over the two year period considered; of these, 4 appeared twice in the list, and one study
was split in two papers, which were regrouped for the analysis. Twenty-four papers were excluded
because they did not meet the criteria we set on the search (date of publication, language and study
performed in humans). Twelve papers were found not to be drug studies, or not to include phase I
data. Finally, one paper was not available from any source we had access to, including direct contact
with the author. In the following, we therefore used a database of 312 papers, of which 40 were read
by the two authors and the remaining by only one author.
Table I gives the main characteristics of the studies. Industrial partnerships were identified based
on co-authorship, financial support, or both in 86 papers (28%). The identification of a statistician
or a pharmacokineticist was based solely on the affiliation which was sometimes limited to the uni-
versity or the pharmaceutical company. As seen from the table, an overwhelming majority of papers
published concerned cancer studies. The main objective of the study was exploratory in 139 papers
(45%, of which 126 cancer studies), regrouping first-in-man or first-in children studies, new formula-
tions, special population including use of drugs in new pathologies, while it was confirmatory in 173
papers (55%, of which 164 cancer studies), with a majority of these being studies evaluating com-
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bination therapies or new administration schedules. We also recorded the specific objectives stated
in the paper: in accordance with the selection criteria, the determination of the PK was an objective
in 84% of the studies (n=262). Because of the number of cancer studies found in the survey, the
determination of the MTD was an objective in 215 studies (69%) and the investigation of toxicities or
DLT in 165 papers (53%). The studies were nearly always designed with multiple objectives in mind
(in N=279 studies, 89%). We also noted that in a few papers, the objective was not clearly stated in
the abstract or the introduction. The number of subjects included in the studies was typically rather
low, as expected from phase I studies, but a few studies included over 100 subjects.
Because we only found 22 papers which investigated non-cancer drugs, these tables and the fol-
lowing results will focus only on the 290 studies in the oncology field. We performed stratified
analyses on the primary objective. The primary objective did not significantly change the proportion
of papers involving a pharmacokineticist or a statistician, nor the proportion of studies performed in
collaboration with an industrial. The size of the study however was slightly larger in confirmatory
studies (median 32, range 6-105) than in exploratory studies (median 28, range 7-91, p<0.05).
3.2 Pharmacokinetic study
Our main focus in this paper was to examine how the PK part of phase I studies was reported. The
results concerning the PK study are reported in table II and III. Of the 290 studies in the oncology
field, 7 did not include PK, so the two tables report the findings on 283 papers.
In the methods section, the description of the PK section was available in most papers; however,
30 papers did not describe the design of the PK study at all or mentioned only the number of samples,
and in 5 the description was insufficient (sometimes describing only partly the sampling schedule or
mentioning weekly samples without the timing). Sampling was performed on at least two occasions
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in 65% of the studies, but in several papers, although the sampling schedule on the first occasion
was described, we could not determine the number of additional samples or their exact timing when
reading the paper. Also the number of subjects included in the PK study could not be found in 34
papers (12%) and was not apparent in many others.
Combination therapies were investigated in 120 papers (table III), of which 113 included 2 drugs
(94%) and 7 included 3 drugs or more (6%). Combination studies represented 54% (n=51) of the
studies performed by academia alone, but only 37% (n=69) of the studies performed with financial
support from the pharmaceutical industry (p<0.007 according to a χ2 test). Only 38 studies however
included double escalation procedures, where the different drugs are escalated separately: in most
cases only the main drug is escalated. Twenty-one of these studies were self-described as PK in-
teraction studies, but in fact 48 studies investigated the interaction between the drugs, although half
considered only the effect of one drug on the PK of the other(s).
PK data was most often analysed by non-compartmental methods (NCA), alone or in combina-
tion with more advanced approaches (n=14). In 21 papers (7%), the reporting was purely descriptive,
showing plots of concentrations versus time or reporting summary statistics of trough or steady-state
concentrations. The method of analysis was not reported at all in 50 papers. Modelling, using pop-
ulation approaches or individual estimation, was used in few papers (20% of the total); in one of
the papers, a model described the PD of the drug but it was unclear whether the PK had also been
modelled. In the 227 papers where the analysis was described and was not descriptive (n=212), the
software used for the analysis was quite often not reported (n=37, 17%); when it was reported, the
software WinNonLin, which can be used for NCA and RNL analyses, was the most frequently cited
(n=119, 56%). As a result of this choice of methodology, the PK variables most often reported were
the area under the curve (AUC) as a measure of drug exposure, observed concentrations such as con-
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centration profiles,peak (Cmax), steady-state (Css, or trough (Ctrough) concentrations, and parameters
obtained through non-compartmental analyses such as the clearance (CL), volume of distribution or
half-life.
Extensive sampling was a rule: the median number of samples collected on a single occasion
was 10 (range 1, for some studies collecting only steady-state samples in routine therapeutic drug
monitoring, to 26), and the total number of samples varied from 2 to 54, with a median of 15; in 30
papers the number of samples was not clearly reported or varied within subjects as the samples were
collected during long-term treatment. There was no difference in the number of samples depending on
whether the method was NCA or RNL versus population methods. The number of subjects reported
in the PK analysis was less than the total number of subjects included in the study in 138 papers.
Reasons for excluding data included "patient’s will to participate in the PK study", or "concentrations
undetectable for low doses", but they were seldom stated explicitly in the paper. PK was investigated
usually at several drug levels and in majority at all drug levels studied (n=207 studies), although this
information was often deduced from the tables reporting the PK results and not explicitly stated, and
sometimes could not be determined (n=24).
Stratified analyses were performed to investigate the differences between papers using basic meth-
ods (descriptive or NCA) versus papers using modelling approaches. Papers published by academia
alone were slightly more likely to involve modelling (non-linear regression or population methods,
22 out of 76) than papers involving an industrial partner (19 out of 157, p<0.003). When modelling
approaches were used, there were also slightly less samples taken (median 33 versus 39 for studies
using NCA), but this trend was not significant. The same results were obtained when assuming that
the papers not reporting the analytical method (n=50) had used basic approaches.
The results of the PK study were usually described in a separate paragraph of the paper, and
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in majority no attempt was made to relate the PK results to the toxicity of the drug, or any other
result from the study (efficacy, evolution of a biomarker...). In 34 papers an attempt was made at
investigating the relationship between PK and toxicity: in 7 papers, this was purely descriptive, in 19
papers, a correlation or regression between a toxicity marker and PK parameters was tested, and in 8
papers a logistic model was used. In 35 papers the relationship between PK and efficacy was studied:
in 7 papers this was descriptive, in 22 papers correlation or regression was used to relate the PK with
the evolution of a biomarker, while in 6 papers logistic regression or modelling was applied. In 64
papers (22%) both efficacy and toxicity were studied in relationship with PK.
4 Discussion
In this paper we present a survey of the papers reporting phase I studies and including PK. The
guidance for PK studies in humans, issued by the FDA, contains a number of recommendations
concerning the content of the report to be filed when a new drug application is submitted [4]. These
items are considered necessary to judge the validity of an application, and although they cannot all be
reported in a scientific article, we used this guidance as a basis to establish the data abstraction form
described in the present paper.
We read 312 papers published over 2005 and 2006 and reporting phase I studies with PK. We
found an overwhelming majority of the papers in our survey to be published in oncology. This reflects
in part a selection bias in our initial Medline search. Indeed, our search included the following criteria;
(1) "Phase I" or "Phase 1" in the title of the published paper, (2) "Phamacokinetic" anywhere, (3)
paper published between 2005 and 2006, (4) clinical trials as search limit, and (5) English paper as
search limit. This Medline search yielded 349 papers in which 37 papers were excluded (review, not
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pharmacokinetic study, etc) and 290 (83%) were oncology clinical trials or related to oncology trials.
Phase I trials in oncology may be more likely to be identified as such in the title. To check this, a
second Medline search was done to estimate the selection bias, in this new search all previous criteria
were similar except the first one, which was changed to "Phase I" or "Phase 1" anywhere. 590 papers
were found in which, based on title and abstract, 422 (71%) papers were identified as oncology or
related to oncology trials, and 67 papers (11%) excluded. Thus, the high percentage of oncology trials
found in the present study is slightly overestimated but oncology trials still represent the majority of
published phase I trials.
The large majority of papers found in oncology with both the initial and modified search is proba-
bly a combination of two factors. The first is a selection bias, in that phase I trials appear more likely
to be identified as such in the oncology field where there may be a more standardised approach to these
studies. The second is a publication bias due to the way subjects are recruited. Indeed, subjects re-
cruited in phase I studies in oncology are usually treated at the hospital and such studies are performed
in collaboration with hospital physicians and researchers, whereas studies in healthy volunteers are
mostly performed within the pharmaceutical industry or increasingly outsourced to clinical research
centers, and publications are not necessarily encouraged. A possible work-around the publication bias
could be to survey Final Study Reports, submitted to and reviewed by Health Authorities. However,
these reports are not readily accessible, and existing registries such as www.clinicalstudyresults.org,
developed by the pharmaceutical industry to provide greater access to the results of its clinical studies,
or www.cancer.gov/clinicaltrials/ct-types-list, include mainly results from later phases in drug develop-
ment.
An industrial partner was involved either as co-author or through financial support, in two-thirds
of the papers surveyed, meaning one-third were purely academia. Support by the pharmaceutical in-
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dustry, in the form of a grant or by furnishing the drug under study, was reported in 40% of the papers
surveyed; however, it was not always clear in the other 60% whether the drug had been furnished,
so this figure may be slightly underestimated. Even so, we expected that most of phase I studies
should involve an industrial partner, since these studies are usually initiated by the pharmaceutical
industry. Again, this could be related to a publishing bias whereby phase I studies performed in the
pharmaceutical industry are not all published.
We also attempted to determine the percentage of studies involving statisticians or pharmacoki-
neticists/pharmacologists, but these items proved tricky to establish. Based on the affiliation reported
alone, we found few departments of statistics or biostatistics explicitly stated, and similarly depart-
ments of pharmacology or pharmacokinetics were seldom found. It is also possible that, when the pa-
pers were published in collaboration with the pharmaceutical industry, the statistical and PK analyses
were performed in-house. Although this does not necessarily mean that statisticians or pharmacoki-
neticists were not part of the project, we did note that the PK analysis was usually quite basic.
In the remaining part of the paper, we focus on oncology trials owing to the limited number of
papers outside this area.
The PK study was usually described in separate paragraphs, both in the methods and the results
section, and rarely related to the other findings in the study such as toxicity. The description of
the methods was usually appropriate, except in a few papers where, as pointed out, sampling times
were not described. However the description of the results were not as standardised, and informa-
tion was often missing. This made it more difficult to find the relevant results, especially for non-
pharmacokineticists. PK results were also frequently reported separately for the different doses, with
no attempt made at providing an overall information which could be extrapolated and used in later
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phases of drug development.
Modelling was seldom applied, and in majority PK data was analysed using non-compartmental
approaches. When modelling was used, it did not appear to have an influence on the design of
the studies. A large number of studies involve measurements on at least two occasions (such as
after 2 doses), as per the recommendation of the regulatory authorities on population PK [13], but
within subject variability was never investigated even though this may be a key point for future drug
administration. Modelling approaches can be useful for decision purposes [3]. PK or PK/PD models
developed using the data from phase I studies can be applied to guide dosage decisions for phase II,
evaluate alternative formulations or drug delivery systems, or investigate alternative dosage regimen
for multiple dose studies [8]. As such, modelling can also play a pivotal role in the drug approval
process [14]. Another point to note is that the number of subjects for which the PK was studied was
often not reported, and in many papers the number of subjects with PK as reported in tables appeared
less than the total number of subjects, while the reason for that was seldom reported. Sometimes the
subjects were considered not be evaluable for PK and their data apparently discarded, but modelling
approaches could have been used to incorporate all the available data even when NCA methods fail.
In a recent survey performed by the FDA concerning the low rate of success of new drug ap-
plications, the department of Pharmacometrics states that "one of the major criticisms against drug
development is its negligence to employ prior knowledge to drive drug development decisions such
as trial design and analysis", leading to the proposal to improve the process [7]. Integrated PK/PD
development has been proposed as a more effective use of knowledge and decision making to be used
prospectively during drug development [15, 8]. In the present survey, we found that seldom was any
attempt made to relate the PK findings to the other results of the study. In particular, hardly ever was
the occurrence of toxicities related to individual PK parameters such as exposure, even though most
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of the studies were cancer studies where toxicities are dose-limiting and interindividual variability
was usually high. It is of course possible that such a study was performed at another time during the
development of the drug, or that it was reported in a separate paper or in the registration file submitted
to the regulatory authorities.
In 2001, Margolin et al. performed a detailed review of clinical trials reporting high-dose chemother-
apy regimens [16]. As we do in the present survey, they noted the lack of correlative pharmacologic
analyses, and suggested guidelines for the design of such trials. Their suggestions included statistical
input into the design, execution, analysis, interpretation, and reporting of these studies, as well as
more homogeneity in the analysis methods [16]. Recent regulatory recommendations have in addition
emphasised the benefits of better integrating all information during the drug development process,
explicitly stating PK [7]. Despite these recommendations however, our study shows that there is still
room for improvement both in the reporting and in the analysis of the PK studies.
Several factors may explain the relative paucity of usable data we found in this survey. First, the
amount of information contained in a phase I clinical trial requires a concise report of the different
sections, including PK. However, some informations like the number of samples, the description of the
sampling schedule, as well as the reasons why some data was discarded, need to be explicitly stated.
In our study, we often had to deduce such information from tables or figures, and sometimes we could
not find it. Second, the emphasis of the publication may be more on the clinical findings than on the
PK; however, in 84% of the papers we surveyed, the determination of the PK of the drug was explicitly
stated as a primary objective and therefore probably deserves a more complete reporting. Third,
the editorial process may also contribute to a standardisation of the reporting, however additional
material can now often published online. Fourth, PK studies are also published in their own right and
more sophisticated modelling may well have been performed after the reporting of the initial study,
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justifying a separate publication. However even in this case it is important to provide in the initial
report a complete description of the data obtained, including the reasons for which some subjects are
not included in the PK analysis.
Quality is a major issue in randomized clinical trials. For instance, the CONSORT (Consolidated
Standards of Reporting Trials) statements were developed, encompassing various initiatives devel-
oped by the CONSORT Group to alleviate the problems arising from inadequate reporting of clinical
trials. Although it can be argued that all randomized controlled trials are not comparable, the CON-
SORT Statement developed a 22-item checklist to evaluate how the trial was designed, analyzed, and
interpreted. In the same way a similar initiative could be realistic in the context of phase I clinical
trials. Recently, Strevel et al. have proposed a quality score to assess the quality of abstract reporting
for phase I cancer trials [17]. Similar quality scales or checklists could be developed to assess the
reporting of the PK studies in published papers.
5 Recommendations
In order to improve the reporting of PK analyses in this field, we suggest improvements in three
main areas: design, reporting of the methods used, and reporting of the results.
First, the design of the PK study should include the study of several, if possible all, doses of the
drug; regulatory authorities are particularly interested in examining "the changes in kinetic parameters
within the recommended dosing range", and suggest examining when appropriate the influences of
demographic characteristics [4]. Although the FDA guideline on human PK in new drug application
did not explicitly mention assessing the within-subject variability when it was issued in 1987, a later
guideline from the same agency and dealing with population pharmacokinetics devotes a subsection
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to the "importance of sampling individuals on more than one occasion" [13], which contributes to
the changes in pharmacokinetic parameters. We therefore recommend to evaluate the within-subject
variability in pharmacokinetic parameters, as well as the between-subject variability. In the present
review, we found that most of the studies we collected administered multiple doses of the drug, which
make this recommendation quite feasible, and a large number already followed it. Finally, around half
of the papers we reviewed studied a combination of drugs; for these studies, sampling of all drugs
should be performed to provide information on individual exposure for each drug.
Second, we recommend that the methods section describe: the number and timing of samples
taken; the range of doses; the method used for the analysis of the PK, clearly stating whether mod-
elling was used; the software and the estimation algorithm; if modelling was used, the method for
data weighting and the model used for residual error; a motivated choice of the PK parameters of
interest; whether PK was related to other findings in the study, and if so, a description of the analysis;
for studies with several drugs, whether drug interaction was studied and the method used, as well as
whether both drugs were escalated separately and the combined scalation scheme.
Third, the results section should contain the following information: the number of subjects in-
cluded at each dose level; the number of subjects with PK and the justification for not including
certain subjects in the pharmacokinetic analysis, the distribution of the estimated parameters at each
dose level; the respective contribution of within and between subject variability for each parameter; a
table summarising PK parameters across all doses if the PK was found to be dose-proportional, and
PK parameters estimated using an appropriate model if it was not.
In addition to these three key areas, we would like to suggest trying to relate the PK findings
to the other results in the study, such as toxicity and/or efficacy. Integration of PK results in the
broader picture of drug development is currently lacking [7], as is a less discontinuous development
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process, and this has not much progressed since previous reviews [16]. For instance, when biomarkers
of the toxicity or the efficacy are measured, modelling can be used to detect a concentration-effect
relationship. The relationship of PK parameters of exposure such as the AUC with binary endpoints
can be studied using logistic regression; boxplots of measures of exposure versus the endpoint can be
plotted and descriptive statistics and correlation tests can be given. In all cases, the information could
be tabulated and stored for use in later studies, possibly in Web appendices. Finally, phase I clinical
trials often include extensive sampling to describe the entire PK profile, which could be more often
modelled to provide a first description of the PK and guide subsequent developments.
6 Conclusion
In conclusion, the present survey showed that there is still progress to be made concerning the
reporting and the analysis of the PK part of phase I clinical trials. The impact of the present survey is
limited to clinical trials in oncology because of the small number of studies that were not related to
cancer drugs. We propose a number of recommendations to improve the reporting of the PK sections
of these trials.
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Tables
Table I : Characteristics of the 312 papers read in the present study. For the items ’Country’, ’Statis-
tician’ and ’Industrial’ the answer ’no’ means ’no’ or ’not reported’.
Item N (%)
Year 2005 171 (55%)
2006 141 (45%)
Country North America 186 (60%)
Europe 90 (29%)
Asia 27 (9%)
other 9 (2%)
Statistician yes 46 (15%)
no 266 (85%)
Pharmacologist/Pharmacokineticist yes 81 (26%)
no 231 (74%)
Industrial partner (*) co-author 172 (55%)
support 126 (40%)
none 100 (32%)
Pathology cancer 290 ( 93%)
infectious disease 7 (2%)
other 15 (5%)
Age adults 289 ( 93%)
children and adults 4 (1%)
children/young 19 (6%)
Population patients 299 ( 96%)
healthy volunteers 13 (4%)
Main study objective first-in-man 79 (25%)
special population or pathology 35 (11%)
formulation 18 (6%)
feasibility 7 (2%)
combination therapy 105 (34%)
schedule evaluation 33 (11%)
PK/PD 18 (6%)
other 17 (5%)
Number of subjects median [range] 26 [6-151]
(*) multiple answers possible
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Table II : Characteristics of the pharmacokinetic study reported in the 283 papers concerning oncol-
ogy trials and including PK.
Item N (%)
Description of PK yes 248 (88%)
partial 5 (2%)
no 30 (10%)
Multiple occasions yes 183 (65%)
no 86 (30%)
Missing 14 (5%)
Analysis method (*) Descriptive 21 (7%)
Non compartmental method (NCA) 171 (60%)
Non linear regression (RNL) 47 (17%)
Population approach (POP) 9 (3%)
Not reported 50 (18%)
Model built yes 48 (17%)
no 235 (83%)
Relationship PK/toxicity yes 34 (12%)
no 246 (87%)
not applicable 3 (1%)
Relationship PK/efficacy yes 35 (12%)
no 241 (85%)
not applicable 7 (2%)
PK variables (*) Observed concentrations 34 (12%)
Cmax, Css, Ctrough,... 196 (69%)
AUC 224 (79%)
NCA parameters 173 (61%)
CL 158 (56%)
PK parameters 12 (4%)
Other 42 (15%)
none reported 13 (5%)
(*) multiple answers possible
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Table III : Multiple or single drug, for the pharmacokinetic study reported in the 283 papers concern-
ing oncology trials and including PK.
Item N (%)
Single drug yes 163 (52%)
no 120 (38%)
Interaction study yes 21 (18%)
(n=120) no 99 (82%)
Double escalation yes 39 (32%)
(n=120) no 81 (68%)
PK studied for associated drugs yes 51 (42%)
(n=120) no 69 (58%)
Interaction studied yes 22 (18%)
(n=120) partial 26 (22%)
no 72 (60%)
Figures
Medline search
Not english language: 4
2006: 164 papers
Published in 2007: 9
Not in humans: 11
Not a drug study: 7
Not phase I: 5
Excluded: 37 papers
2005: 185 papers
312 papers
Unavailable: 1 
